Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166 Pipeline Review, H1 2018
Summary
Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166 pipeline Target constitutes close to 12 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Heparanase Pipeline Review, H1 2018, outlays comprehensive information on the Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166 Heparanase is an endoglycosidase which cleaves heparan sulfate HS and hence participates in degradation and remodeling of the extracellular matrix ECM. Heparanase is preferentially expressed in human tumors and its overexpression in tumor cells.
The enzyme also releases angiogenic factors from the ECM and thereby induces an angiogenic response. Heparanase exhibits also nonenzymatic activities, independent of its involvement in ECM degradation. Among these, are the enhancement of Akt signaling, stimulation of PI3K and p38dependent endothelial cell migration, and up regulation of VEGF, all contributing to its potent proangiogenic activity. Inhibiting the enzyme is beneficial in treatment of cancer.
The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 2 and 4 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Metabolic Disorders, Immunology, Ophthalmology and Gastrointestinal which include indications Diabetic Nephropathy, Age Related Macular Degeneration, Breast Cancer, Colitis, Dry Atrophic Macular Degeneration, Head And Neck Cancer, Inflammation, Metastatic Cancer, Refractory Multiple Myeloma, Retinopathy, Solid Tumor, Transplant Rejection, Type 1 Diabetes Juvenile Diabetes, Type 2 Diabetes and Wet Neovascular / Exudative Macular Degeneration.
Furthermore, this report also reviews key players involved in Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166
The report reviews Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166 targeted therapeutics and enlists all their major and minor projects
The report assesses Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Heparanase Endo Glucoronidase or Heparanase 1 or HPSE or EC 3.2.1.166 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope